Published: Jul, 2017
The global market for inhalation and nasal spray generic drugs features a largely fragmented, not to mention intensely competitive owing to pricing pressures, vendor landscape, with the top four companies accounting for a nearly 46% of the overall market in 2014, observes Transparency Market Research (TMR) in a recent report. These leading companies, namely Sandoz International GmbH, Mylan N.V., Allergan PLC, and Teva Pharmaceutical Industries Ltd., are focusing on growth strategies such as geographical expansion and mergers and acquisitions across high-growth potential regional markets.
Regional markets such as Asia Pacific and Latin America show immense growth promise for generic drugs owing to the cost-conscious consumer base. However, these regions present immense challenge for new companies owing to the presence of a large number of local and regional players. Nevertheless, strategic collaborations could enable international companies to establish their businesses. TMR estimates that the global inhalation and nasal spray generic drugs market will exhibit a 5.5% CAGR over the period between 2015 and 2023, rising to a valuation of US$35 bn by 2023.
Asia Pacific to Lead to Healthy Growth Avenues for Inhalation and Nasal Spray Generic Drugs
On the basis of drug class, the segment of combinations, which accounted for the dominant share in revenue in 2014 and 2015, is expected to remain the leading drug class over the report’s forecast period as well. The segment is expected to reach the valuation of US$6.4 bn in 2016. In terms of geography, the market for inhalation and nasal spray generic drugs in Asia Pacific is projected to emerge as the regional market with the most promising growth opportunities over the forecast period. The two leading regional markets in the present scenario - North America and Europe, will continue to constitute the top share in terms of revenue contribution over the forecast period, but will lead to less promising growth opportunities as compared to Asia Pacific owing chiefly to mature marketplaces and more preferences to branded drugs.
Cost Effectiveness of Generic Drugs Help Boost Sales
Looming patent expirations of some of the leading drug classes prescribed for a number of inhalation-related conditions is one of the key factors boosting the sales of generic inhalation and nasal spray drugs. The substantially low costs of generic drugs are also a key factor behind the higher preference given to them across cost-conscious regions.
The increased awareness regarding the significant reduction in the cost burden of treatment of a number of commonly occurring diseases on the overall healthcare funds of a country are also compelling government and healthcare authorities to educate masses about the variety of generic drugs available in the market. Moreover, the vast rise in prevalence of breathing-related conditions such as chronic obstructive pulmonary disease and asthma across the globe and the rising demand to lower down healthcare costs are also expected to drive the market.
Stringent Regulations in Emerging Economies Could Hinder Growth Prospects
Owing to the large number of companies foraying into the generics sector for inhalation and nasal spray drugs, quality and integrity of generic inhalers is increasingly becoming a cause of concern for the masses as well as authoritative healthcare bodies in emerging economies. Countries such as Brazil and India are increasingly featuring strict regulations concerned with the process of approving new generics. These regulations are expected to hinder the growth opportunities of the global inhalation and nasal spray generic drugs market to a certain extent in the next few years.
The information presented in this analytical take of the global inhalation and nasal spray generic drugs market is based on a Transparency Market Research report, titled “Inhalation and Nasal Spray Generic Drugs Market (Drug Class - Corticosteroids (Fluticasone, Budesonide, Beclomethasone, Flunisolide, Mometasone, and Ciclesonide), Bronchodilators (Albuterol and Epinephrine), Antihistamines, Combinations (Salmeterol/Fluticasone, Formoterol/Budesonide, and Azelastine/Benzalkonium Chloride), Decongestant Sprays (Phenylephrine hydrochloride and Oxymetazoline hydrochloride); Disease - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, and other Respiratory Diseases) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453